Ginkgo bioworks stock prediction.
Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%. Analysts expect adjusted earnings to reach $-0.442 per share for the current fiscal year.
Ginkgo Bioworks. 11 Aug, 2022, 07:05 ET. SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic. CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 ...Ginkgo Bioworks (DNA 8.53%) is a biotech unlike any other, and it's no surprise why it's consistently attracting the attention of bigwig portfolio managers like Cathie Wood.Real time Ginkgo Bioworks (DNA) stock price quote, stock graph, news & analysis.Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
The Ferment Co is a company creation studio for the next wave of synthetic biology product companies. The Ferment Co is powered by Ginkgo Bioworks, the world's most advanced platform for cell programming. Learn more at www.Ferment.co. Forward-Looking Statements of Ginkgo BioworksAll information and data on the website are for reference only and no historical data shall be considered as the basis for predicting future trends. Information ...
Presentation and Q&A session scheduled for post-market on Wednesday, March 1, 2023. BOSTON, Feb. 22, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for …49.41M. AMZN. 145.18. +1.65%. 47.06M. View today's Ginkgo Bioworks Holdings stock price and latest DNA news and analysis. Create real-time notifications to follow any changes in the live stock price.
Mar 30, 2022 · There are some variant perceptions on Ginkgo Bioworks Holdings, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$6.00 per share. Note the wide gap in analyst price ... Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo's ...Days after trading under its new ticker after completing its SPAC merger with Soaring Eagle Acquisition, Ginkgo Bioworks (NYSE:DNA) is rising higher today, having climbed 5.8% at 11:12 a.m. EDT ...Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used in developing ...
١٥ جمادى الأولى ١٤٤٤ هـ ... Ginkgo Bioworks Stock Forecast - Analyst Ratings. Eight FactSet analysts have an Overweight consensus rating on DNA stock with a share price ...
Ginkgo Bioworks Holdings Inc. 1.43. Delayed Data. As of Dec 01. +0.135 / +10.47%. Today’s Change. 1.12. Today ||| 52-Week Range. 2.55.
Mar 1, 2023 · Forward-Looking Statements of Ginkgo Bioworks This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of operations, both ... DNA Stock Surges on Analyst Report. Yesterday, a Raymond James analyst initiated coverage on Ginkgo Bioworks, providing an outperform rating. This outperform rating came alongside a $14.50 price ...DNA Stock Forecast: Welcome to our series of Stock Forecasts, Predictions and Price Targets for 2023, 2024, 2025, 2030.Today we will analyse stocks from both technical and fundamental analysis and today’s stock is- DNA, DNA Stock Forecast 2023, 2024, 2025, 2030, 2040, 2050.According to About.com, the fate of the children born on Wednesday in the poem “Monday’s Child” is that the child is full of woe. This poem was first written in 1838, but it is not believed that people ever really put much stock into its pr...Which Ginkgo Bioworks insiders have been buying company stock? The following insider purchased DNA shares in the last 24 months: Shyam Sankar ($512,000.00). How much insider buying is happening at Ginkgo Bioworks?Ginkgo Bioworks Holdings Stock Forecast, - WalletInvestor.com
The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction. See More Share. DNA Stock Quotes API ...Bayer announced that the company has closed the previously announced transaction with Ginkgo Bioworks to begin a multi ... Here's a complete rundown of Wall Street's 2024 stock market predictions.The last reported sale price of Ginkgo's Class A common stock on November 15, 2022 was $2.67 per share. The underwriter proposes to offer for sale the shares of common stock from time to time in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related ...Sep 20, 2023 · On that note, on August 29 Ginkgo Bioworks ( DNA 5.80%) announced that it is joining forces with Alphabet, Google's parent company, in a five-year strategic partnership to develop and use new ... Ginkgo Bioworks Holdings, Inc. (DNA) NYSE - Nasdaq Real Time Price. Currency in USD Follow 2W 10W 9M 1.4200 +0.1300 (+10.08%) As of 03:32PM EST. Market open. 1d 5d 1mSep 20, 2023 · On that note, on August 29 Ginkgo Bioworks ( DNA 5.80%) announced that it is joining forces with Alphabet, Google's parent company, in a five-year strategic partnership to develop and use new ... BOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December ...
Gingko Bioworks (NYSE:DNA) is bringing this science to the next level by introducing the power of AI to its toolkit. Ginkgo Bioworks promises that they can design and test microorganisms cheaper ...
How This Affects DNA Stock. Ginkgo Bioworks securing an $18 million contract over a four-year period is exciting investors. It shows the company’s research is valued by a government agency ...3.90. Nikko Asset Management Americas, Inc. 3.67. ARK Genomic Revolution ETF. 3.25. The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and DNA history to help you invest and ...Aug 22, 2023 · Ginkgo Bioworks. Wood has dipped her toes into the nascent eTVOL industry, but she's already ankle-deep in Ginkgo Bioworks' (DNA-2.52%) biofoundry platform. After the company bought millions more ... Aug 24, 2021 · Antonio Regalado. August 24, 2021. Mz Tech. The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic ... The 7 analysts offering 12-month price forecasts for Ginkgo Bioworks Holdings Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.25.We expect investors to focus on the sales performance of Ginkgo Bioworks Holdings, Inc.’s DNA two business units when the company reports third-quarter 2023 results on Nov 8 after market close.Nov 21, 2023 · Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%. Analysts expect adjusted earnings to reach $-0.442 per share for the current fiscal year.
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and ...
Ginkgo Bioworks Stock Price, News & Analysis (NYSE:DNA) $1.42 +0.14 (+10.89%) (As of 12/1/2023 ET) Compare Today's Range $1.28 $1.43 50-Day Range …
Ginkgo Bioworks Holdings Inc (DNA) stock is trading at $1.42 as of 9:36 AM on Monday, Dec 4, a loss of -$0.01, or -1.05% from the previous closing price of $1.43. …Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a …The current Ginkgo Bioworks Holdings [ DNA] share price is $1.43. The Score for DNA is 19, which is 62% below its historic median score of 50, and infers higher risk than normal. DNA is currently trading in the 10-20% percentile …Gingko Bioworks (NYSE: DNA) stock is up more than 10% today after its latest earnings report. Ginkgo Bioworks reported that its fourth-quarter 2021 revenue increased 363% year over year to $148 ...While Ginkgo Bioworks is an exciting company, the pricing of the SPAC stock leaves a lot of room for things to go wrong between now and the company's long …In about an hour following the publication of Scorpion’s 175-page report, Ginkgo’s stock price dropped at least 20%, down to about $9.50 a share.By William White, InvestorPlace Writer Jul 19, 2023. Ginkgo Bioworks (DNA) stock is rising higher on Wednesday after the company won a four-year, $18 million contract from DARPA.Their UNCY share price targets range from $4.00 to $24.00. On average, they expect the company's share price to reach $10.83 in the next twelve months. This suggests a possible upside of 2,013.8% from the stock's current price. View analysts price targets for UNCY or view top-rated stocks among Wall Street analysts.We asked three Motley Fool contributors to pick beaten-down stocks they think can deliver 5x gains by 2030. Here's why they chose CRISPR Therapeutics ( CRSP -0.74%), Ginkgo Bioworks Holdings ( DNA ...Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%. Analysts expect adjusted earnings to reach $-0.442 per share for the current fiscal year.Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ...Find real-time DNA - Ginkgo Bioworks Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ginkgo Bioworks Holdings Inc (NYSE:DNA) Real-Time Quotes. 1.37.
Get the latest Ginkgo Bioworks (DNA+) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.One of the best-performing stocks in today’s market is biotech company Ginkgo Bioworks (NYSE:DNA).Shares of DNA stock rocketed more than 20% higher in early afternoon trading.Nov 30, 2023 · Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for DNA stock stock is $1.88, which predicts an increase of 45.74%. The lowest target is $1.25 and the highest is $2.50. On average, analysts rate DNA stock stock as a sell. Ginkgo Bioworks ( DNA -6.54%) is a biotech that's operating on multiple bleeding edges of innovation as it works to engineer and manufacture biological cells at scale. Between its highly automated ...Instagram:https://instagram. ste'microsectorsbest medicare supplement plans in pennsylvaniamomo stocks Key Insights. Ginkgo Bioworks Holdings' estimated fair value is US$1.81 based on 2 Stage Free Cash Flow to Equity. Current share price of US$1.33 suggests Ginkgo Bioworks Holdings is potentially ...BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today preliminary performance updates for ... carro rivian preciocompare wealth management firms Price Target. Based on short-term price targets offered by eight analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $3.46. The forecasts range from a low of $1.25 to a ... mint moble stock Bayer announced that the company has closed the previously announced transaction with Ginkgo Bioworks to begin a multi ... Here's a complete rundown of Wall Street's 2024 stock market predictions.Simply Wall St Published November 13, 2023 Source: Shutterstock The analysts covering Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA) delivered a dose of …We asked three Motley Fool contributors to pick beaten-down stocks they think can deliver 5x gains by 2030. Here's why they chose CRISPR Therapeutics ( CRSP -0.74%), Ginkgo Bioworks Holdings ( DNA ...